Initiation of Phase 1/2 Combination Clinical Trial with Evelo’s Monoclonal Microbial, EDP1503, and KEYTRUDA® (pembrolizumab) Across Various Indications Expected in First Half of 2019 Evelo Biosciences, Inc.. a clinical-stage biotechnology company developing monoclonal...
Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of version 2.3 of its Trial Simulator software to help drug developers improve clinical trial design, resulting in...
Multi-site clinical study brings together the best in class tumor-targeting imaging agent for brain cancer and the highest sensitivity NIR microscope-based detection device in late stage development Blaze Bioscience Inc., the Tumor Paint Company®, a biotechnology...
Tiziana Life Sciences plc (“Tiziana” or the “Company”) (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, previously announced that it had submitted...
Cold Genesys, Inc. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Cold Genesys’ lead oncolytic immunotherapy candidate CG0070 with Merck’s anti-PD-1...
Email
Text